VLDL Cholesterol Calculator

What is VLDL cholesterol?

Very-low-density lipoproteins are particles made by the liver to transport triglycerides to muscle and fat tissue.

Each particle also carries cholesterol and one apolipoprotein B100 molecule. Lipoprotein lipase removes triglycerides from VLDL, producing smaller remnants and intermediate-density lipoproteins. Some particles are cleared by the liver and others become LDL. VLDL cholesterol, written VLDL-C, means the cholesterol mass inside VLDL particles. It is not the same as the VLDL particle count, triglyceride concentration, or remnant cholesterol. Routine lipid panels usually do not measure VLDL-C directly. A reported VLDL-C value may be a calculation based on triglycerides.

VLDL remnants can enter the artery wall and carry more cholesterol per particle than LDL. Genetic, epidemiologic, and mechanistic evidence links triglyceride-rich lipoproteins and their remnants with atherosclerotic cardiovascular disease. Clinical care still focuses on the complete lipid pattern and absolute risk rather than a standalone calculated VLDL target.

[1][2][3]

The triglycerides divided by 5 estimate

The conventional estimate in mg/dL is: VLDL-C = triglycerides ÷ 5. In mmol/L, the corresponding equation is: VLDL-C = triglycerides ÷ 2.2.

The formula came from the Friedewald LDL calculation and assumes that fasting VLDL carries triglyceride and cholesterol in an approximately 5:1 mass ratio. The estimate is intended for a fasting sample with triglycerides below 400 mg/dL. Even within that range, particle composition varies with triglyceride concentration, diabetes, insulin resistance, alcohol use, genetic disorders, and recent food intake. Modern LDL equations no longer assume one fixed ratio for every sample.

Do not interpret the calculated value as a direct assay. A laboratory may label triglycerides ÷ 5 as VLDL cholesterol, while another laboratory may omit VLDL-C and report non-HDL cholesterol. The method on the report determines whether values from different laboratories are comparable.

[3][4]

Worked VLDL examples

Example 1: fasting triglycerides are 125 mg/dL. Estimated VLDL-C is 125 ÷ 5 = 25 mg/dL. If total cholesterol is 190 mg/dL and HDL-C is 50 mg/dL, non-HDL cholesterol is 140 mg/dL.

The VLDL estimate describes only one assumed portion of that broader atherogenic cholesterol total. Example 2: fasting triglycerides are 300 mg/dL. The fixed formula gives VLDL-C of 60 mg/dL. Accuracy is weaker at this triglyceride level because VLDL composition is more variable. Review the laboratory LDL method, non-HDL cholesterol, glucose status, alcohol intake, medicines, and prior fasting values.

Example 3: triglycerides are 600 mg/dL. Dividing by 5 produces 120 mg/dL, but the formula is outside its intended range. The useful finding is severe hypertriglyceridemia, not the calculated VLDL-C. Clinical evaluation should focus on pancreatitis risk, secondary causes, and a fasting confirmation when the original sample was nonfasting.

[4][5]

How to use this VLDL calculator

Copy the triglyceride result and unit from a fasting lipid panel.

Confirm that triglycerides are below 400 mg/dL or 4.5 mmol/L before using the fixed formula. Select the matching unit, calculate once, and round to a whole mg/dL or two decimal places in mmol/L. Read the estimate beside total cholesterol, HDL-C, laboratory-reported LDL-C, and non-HDL cholesterol. Record fasting duration, collection date, alcohol use near the test, current medicines, diabetes control, recent illness, and any treatment change. These details can explain more than the calculated VLDL number.

Do not use VLDL-C to start a triglyceride medicine, alter a statin, or diagnose a genetic disorder. Use the result to ask whether triglycerides need confirmation and whether non-HDL cholesterol or apoB would better represent atherogenic burden. Keep the original laboratory report for clinician review.

If triglycerides are 500 mg/dL or higher, contact a clinician promptly. A fasting level at or above 1,000 mg/dL carries substantial pancreatitis risk and may reflect chylomicronemia. Severe upper abdominal pain, vomiting, fever, or pain radiating to the back requires urgent medical assessment.

[5][6][7]

How to interpret the estimate

No current US guideline uses a calculated VLDL-C cutoff by itself to diagnose disease or choose treatment.

A value below 30 mg/dL is often printed as a laboratory reference based on triglycerides below 150 mg/dL, since 150 ÷ 5 = 30. This is arithmetic tied to a triglyceride boundary, not an independently validated VLDL diagnosis. Mild to moderate triglyceride elevation often reflects increased hepatic VLDL production. At much higher triglyceride levels, reduced lipolysis and accumulating chylomicrons become more prominent. The fixed formula cannot identify which particles carry the triglycerides and becomes least reliable where clinical risk is highest.

Non-HDL cholesterol equals total cholesterol minus HDL-C and includes VLDL, remnants, IDL, LDL, and lipoprotein(a). Remnant cholesterol is commonly estimated as total cholesterol minus HDL-C minus LDL-C. Neither is synonymous with VLDL-C, and remnant cholesterol inherits error from the LDL method.

[1][5][8]

Fasting, meals, and repeat testing

Nonfasting lipids are acceptable for initial cardiovascular screening in many adults. The triglycerides divided by 5 VLDL estimate assumes a fasting sample.

Chylomicrons appear after meals and change the triglyceride to cholesterol relationship. Their contribution cannot be separated from VLDL with this formula. A clinician may request a fasting repeat after elevated nonfasting triglycerides, for suspected genetic dyslipidemia, or to evaluate persistent hypertriglyceridemia. ACC guidance defines persistence using repeat fasting measurements after lifestyle intervention, stable indicated statin treatment, and management of secondary causes. One result does not establish persistence.

Acute illness, uncontrolled diabetes, pregnancy, rapid weight change, alcohol, and recent dietary intake can shift triglycerides. Compare trends under similar conditions. Do not stop diabetes medicine or fast when doing so could be unsafe; obtain instructions from the ordering clinician.

[5][6][9]

Causes of elevated triglycerides and VLDL

Common causes include insulin resistance, poorly controlled diabetes, obesity, chronic kidney disease, hypothyroidism, pregnancy, liver disease, high alcohol intake, and diets rich in refined carbohydrate or excess energy.

The liver often responds to excess fatty acid supply by producing more VLDL. Medicines can contribute, including some beta blockers, thiazide diuretics, glucocorticoids, oral estrogens, retinoids, antipsychotics, HIV protease inhibitors, immunosuppressants, and bile acid sequestrants. A clinician weighs the lipid effect against the medicine benefit and selects alternatives when appropriate. Do not stop prescribed treatment without review.

Genetic contributors range from common polygenic susceptibility to rare defects in lipoprotein lipase pathways. Severe triglyceride elevation often reflects genetic susceptibility plus a secondary trigger. Familial chylomicronemia, multifactorial chylomicronemia, familial combined hyperlipidemia, and dysbetalipoproteinemia require different evaluation and management.

[5][6][9]

Cardiovascular risk and pancreatitis risk

For mild or moderate hypertriglyceridemia, clinicians assess atherosclerotic risk through LDL-C, non-HDL-C, apoB when useful, and the person’s broader risk profile.

Triglyceride-rich remnants carry cholesterol into the artery wall, but trials do not support prescribing treatment to reach a calculated VLDL-C target. Pancreatitis concern rises as triglycerides become severe, especially at or above 1,000 mg/dL. There is no sharp value below which pancreatitis is impossible. Prior pancreatitis, diabetes control, alcohol, pregnancy, medicines, and genetic chylomicronemia alter risk. Gallstones and alcohol remain common alternative causes of acute pancreatitis.

Management priorities differ by level and cause. LDL-based prevention remains central for atherosclerotic risk, while severe hypertriglyceridemia requires rapid reduction of triglyceride exposure through clinician-directed diet, treatment of hyperglycemia or other secondary causes, and selected prescription therapy. A VLDL calculator cannot choose among these paths.

[1][5][6][10]

Population and life-stage caveats

Children and adolescents use age-specific triglyceride thresholds and pediatric pathways.

Treatment decisions are generally based on fasting values, and drug evidence is more limited than in adults. Severe or persistent pediatric hypertriglyceridemia warrants specialist input rather than adult VLDL reference ranges. Triglycerides normally rise during pregnancy and can become dangerous in a person with an underlying lipid disorder. Obstetric and lipid specialists should interpret marked elevation. Older adults and people with kidney or liver impairment also need medication and dietary plans adapted to comorbidity.

Average triglyceride distributions differ across sex, age, and population groups, while access to testing, diet, medicines, and metabolic disease affect observed values. These differences do not justify race-specific VLDL formulas. The fixed ratio has not been validated as equally accurate in every ancestry or disease state.

[4][9][11]

Limitations and differential interpretation

The calculation assumes all relevant fasting triglycerides reside in VLDL with a fixed composition. It fails when chylomicrons or cholesterol-enriched remnants contribute substantially.

Dysbetalipoproteinemia can produce a triglyceride to VLDL cholesterol ratio close to 1:1, far from the assumed 5:1 ratio. VLDL-C does not measure particle number, particle size, remnant clearance, liver fat, insulin sensitivity, or plaque. A high estimate cannot distinguish overproduction from impaired lipolysis. A normal estimate cannot exclude elevated LDL-C, lipoprotein(a), diabetes, fatty liver disease, or cardiovascular disease.

Direct and specialized remnant assays are not interchangeable and lack broad standardization. Ultracentrifugation can separate lipoprotein classes for research or selected diagnostic work, but routine treatment does not require direct VLDL measurement. Use standardized lipid measures that can change the care plan.

[1][3][8][9]

When clinical confirmation is required

Clinical confirmation is required for triglycerides at or above 500 mg/dL, repeated unexplained elevation, prior pancreatitis, pregnancy with high triglycerides, suspected genetic disease, or discordant lipid results.

Evaluation may include a fasting panel, A1C or glucose, thyroid testing, kidney and liver tests, medication review, alcohol history, apoB, and family history. A fasting triglyceride result at or above 1,000 mg/dL deserves urgent clinician-directed management even without symptoms. Severe abdominal pain with nausea or vomiting may indicate pancreatitis and requires urgent care. Do not wait for a calculated VLDL result.

For lower persistent elevations, treatment begins with the cause and the person’s overall risk. Weight management when indicated, physical activity, glycemic control, limiting alcohol, and choosing a diet suited to the triglyceride level can lower VLDL production. Severe hypertriglyceridemia needs a different dietary plan from modest elevation, so clinical guidance is necessary.

[5][6][7][9]

How it works

VLDL (mg/dL) ≈ Triglycerides / 5. Assumes normal TG composition.

Frequently asked questions

• What is normal VLDL?VLDL below 30 mg/dL is generally considered normal.

Related calculators

References

1. Ginsberg et al.. Triglyceride-Rich Lipoproteins and Their Remnants: Consensus Statement
2. Miller et al.. Triglycerides and Cardiovascular Disease: A Scientific Statement
3. Friedewald, Levy, and Fredrickson. Estimation of the Concentration of LDL Cholesterol in Plasma
4. Feingold et al.. The Measurement of Lipids and Lipoproteins for Diagnosis and Treatment
5. American College of Cardiology. ACC Consensus on ASCVD Risk Reduction in Hypertriglyceridemia
6. Berglund et al.. Evaluation and Treatment of Hypertriglyceridemia
7. Christian et al.. Hypertriglyceridemia and Acute Pancreatitis
8. Wilson et al.. Lipid Measurements in the Management of Cardiovascular Diseases
9. Blackett, Wilson, and McNeal. Secondary Hypertriglyceridemia
10. American Diabetes Association. Standards of Care in Diabetes: Cardiovascular Disease and Risk Management
11. American Heart Association. Pediatric Hypertriglyceridemia: A Scientific Statement